Hepatitis C: Who should treat hepatitis C virus? The role of the primary care provider

Tran, Tram T.

doi:10.1002/cld.692

Cited by 9 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are supported by multiple studies that show HCV treatment through primary care is effective and may increase treatment uptake [ 28 – 30 ]. Despite these early data from non-liver specialist settings, concerns regarding safe use of HCV medications may remain, creating barriers for non-liver specialist HCV treatment uptake [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, these data may impact treatment guidelines, particularly in countries adopting decentralized HCV care, working towards simplified 8-week treatment for the majority of patients with HCV. These results may provide clinical confidence to physicians and other non-liver specialists treating HCV with the opportunity to expand the treater pool, a necessary step to meet elimination targets [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

et al. 2021

View full text Add to dashboard Cite

Introduction More than 70 million people are estimated to be infected with hepatitis C virus (HCV) globally. If left untreated, HCV infection can lead to complications such as extensive liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evolution of treatments has resulted in highly effective and well-tolerated all-oral direct-acting antivirals. The pangenotypic regimen of glecaprevir/pibrentasvir is approved for treating HCV for patients without cirrhosis or with compensated cirrhosis (CC). Guidelines have evolved to simplify treatment to enable non-specialists to manage and treat HCV-infected patients. Simultaneously, such treatment algorithms provide guidance on the pretreatment identification of small subsets of patients who may require specialist treatment and long-term follow-up for advanced liver disease, including those at risk of developing HCC. This study describes the safety profile of glecaprevir/pibrentasvir in patients identified using previously described noninvasive laboratory measures who may be eligible for treatment by non-liver specialists. Methods This post hoc analysis of glecaprevir/pibrentasvir in patients, identified by noninvasive laboratory measures, intended to exclude patients with advanced liver disease and severe renal impairment, who can be managed within non-liver specialist settings. Patients were included from clinical trials and real-world studies of glecaprevir/pibrentasvir for HCV treatment. Baseline demographics, clinical characteristics, and safety assessments, including adverse events and laboratory abnormalities, were summarized. Results Data across these large-scale studies confirm that glecaprevir/pibrentasvir is well tolerated across different patient populations, with fewer than 0.1% of patients experiencing a serious adverse event related to treatment drugs, and few patients developing HCC during or after treatment. Conclusion The safety profile of glecaprevir/pibrentasvir enhances the confidence of non-liver specialists to treat the majority of HCV-infected patients, and provides an opportunity to expand the treater pool, potentially increasing diagnosis and treatment rates for HCV, contributing to elimination of HCV. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01753-3.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The USA Preventative Services Task Force (USPSTF) recommends screening all adults above the age of 18 for CHC[ 4 ]. PCPs play a crucial role in screening, enabling more patients to be diagnosed and treated[ 5 ]. With current regimens being a lot less complicated, PCPs can appropriately provide treatment for these patients, minimizing care costs, referrals, and fewer patients lost to follow up.…”

Section: Discussionmentioning

confidence: 99%

Impact of hepatitis C remission on glycemic control in patients with type 2 diabetes mellitus: primary care outpatient experience

Tripathi

Loganathan

Trivedi

et al. 2021

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

“…This would benefit the communities and the PCP would be critical to expanding access to HCV treatment for the large number of individuals infected with HCV. [20]…”

Section: Discussionmentioning

confidence: 99%

Menace of Hepatitis C virus among multitransfused thalassemia patients in Balasore district of Odisha state in India

Sinha

Raghuwanshi

Mishra

2019

J Family Med Prim Care

View full text Add to dashboard Cite

Context:Hepatitis C virus (HCV) is a potential cause of morbidity and mortality worldwide. It is most commonly transmitted through injecting drug use; the reuse or inadequate sterilization of medical equipment and the transfusion of unscreened blood products. Management of thalassemia requires long-term blood transfusion. Though it improves the overall survival, it carries a definite risk of infection which is expected to be higher in resource limited settings.Aims:To find the percentage of transfusion-transmitted infections (TTIs) in multitransfused patients of thalassemia in Eastern India.Settings and Design:The study was conducted to assess blood safety in rural population in India by measuring the percentage of TTIs including HCV in multitransfused thalassemia patients.Methods and Materials:One hundred and twenty three patients with major beta-thalassemia were enrolled in this study. The blood samples were tested using ELISA technique for all TTIs. HIV fourth generation kits, HbsAg, HCV third generation kits, malaria and syphilis, parbovirus IgM and parbovirus IgG kits, HEV Antigen and IgM antibody were used.Statistical Analysis Used:Proportions and means were calculated for categorical and continuous variables, respectively. Chi-square test was applied and P value of <0.05 was taken as significant.Results:The mean age of patients was 9.5 years ± 5.2 years. Among various TTIs, Hepatitis C and HIV was prevalent among 59.3% and 4.1% of the study participants, respectively.Conclusions:The causes of high prevalence of HCV may be due to donors being usually asymptomatic in early stages, despite being screened for HCV possibly due to missing early window period infections. The screening methodology of TTIs particularly HCV at the district and village level and consequent increased prevalence of HCV in multitransfused rustic population of India shows the extent of blood safety.

show abstract

Hepatitis C: Who should treat hepatitis C virus? The role of the primary care provider

Abstract: http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/11-3-reading-tran a video presentation of this article http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/11-3-interview-tran the interview with the author

Cited by 9 publications

References 4 publications

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

Impact of hepatitis C remission on glycemic control in patients with type 2 diabetes mellitus: primary care outpatient experience

Menace of Hepatitis C virus among multitransfused thalassemia patients in Balasore district of Odisha state in India

Contact Info

Product

Resources

About